» Articles » PMID: 36304648

Palmoplantar Plaque Psoriasis is Associated with Diabetes, Hypertension, Obesity, and Metabolic Syndrome-A Case-Control Study

Overview
Specialty Dermatology
Date 2022 Oct 28
PMID 36304648
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Palmoplantar plaque psoriasis is a regional variant of psoriasis, characterized by erythematous, indurated plaques with fissuring over palms and soles. Chronic plaque psoriasis is associated with various comorbidities such as obesity, diabetes mellitus, hypertension, dyslipidemia, metabolic syndrome, and cardiovascular disease. Body surface area involvement is an indicator of psoriasis severity, and most comorbidities are more strongly correlated with severe disease.

Objectives: To estimate the prevalence of metabolic comorbidities in palmoplantar plaque psoriasis.

Methods: It is a case-control study involving treatment naïve palmoplantar plaque psoriasis patients and age- and gender-matched healthy controls.

Results: The study included 100 cases and 100 controls. The mean age among cases and controls was 45.4 ± 11.1 and 43.9 ± 10.3 years, respectively (: 0.31). The gender ratio among cases and controls was 1.56 (61M: 39F) and 1.94 (66M: 34F), respectively. Comorbidities including metabolic syndrome (: 0.001), obesity (: 0.001), diabetes mellitus (: 0.001), and hypertension (: 0.001) were more common among cases as compared to controls. The odds of diabetes, metabolic syndrome, hypertension, and obesity in patients with palmoplantar psoriasis were 4.8 (95% CI 2.5-9.3), 3.7 (95% CI 2-6.9), 3.1 (95% CI 1.6-6), and 3.5 (95% CI 1.9-6.4), respectively.

Conclusion: In this study, we found that palmoplantar plaque psoriasis is associated with metabolic comorbidities. Primary care physicians should screen patients with palmoplantar psoriasis for these comorbidities.

Citing Articles

Association between body roundness index and psoriasis among US adults: a nationwide population-based study.

Bai G, Peng Y, Liu Q, Shao X, Zhan Y, Chen A Lipids Health Dis. 2024; 23(1):373.

PMID: 39538202 PMC: 11559072. DOI: 10.1186/s12944-024-02365-w.


Pathophysiological Mechanisms and Clinical Associations of Non-Alcoholic Fatty Pancreas Disease.

Pagkali A, Makris A, Brofidi K, Agouridis A, Filippatos T Diabetes Metab Syndr Obes. 2024; 17:283-294.

PMID: 38283640 PMC: 10813232. DOI: 10.2147/DMSO.S397643.


Prevalence of metabolic syndrome and chronic inflammation in psoriasis before and after biologic therapy: a prospective study.

Timis T, Beni L, Florian I, Orasan M, Orasan R Med Pharm Rep. 2023; 96(4):368-383.

PMID: 37970199 PMC: 10642736. DOI: 10.15386/mpr-2631.

References
1.
Menter M, Armstrong A, Gordon K, Wu J . Common and Not-So-Common Comorbidities of Psoriasis. Semin Cutan Med Surg. 2018; 37(2S):S48-S51. DOI: 10.12788/j.sder.2018.011. View

2.
Greenberg R, Goldsmith T, Zeltser D, Shapira I, Berliner S, Rogowski O . Comorbidities in patients with palmoplantar plaque psoriasis. J Am Acad Dermatol. 2020; 84(3):639-643. DOI: 10.1016/j.jaad.2020.03.112. View

3.
Farley E, Masrour S, McKey J, Menter A . Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009; 60(6):1024-31. DOI: 10.1016/j.jaad.2008.11.910. View

4.
Brunasso A, Puntoni M, Aberer W, Delfino C, Fancelli L, Massone C . Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol. 2013; 168(6):1243-51. DOI: 10.1111/bjd.12223. View

5.
Dogra S, Mahajan R . Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016; 7(6):471-480. PMC: 5134160. DOI: 10.4103/2229-5178.193906. View